News & Updates

Show Multimedia Only
Oral HRS-7535 shows promise in glycaemic control for T2D patients

Oral HRS-7535 shows promise in glycaemic control for T2D patients

16 Oct 2026 byStephen Padilla

Use of the once-daily oral HRS-7535, an investigational small-molecule GLP-1 receptor agonist (RA) for type 2 diabetes (T2D) and weight management, demonstrates noninferiority to dapagliflozin for glycated haemoglobin (HbA1c) reduction in Chinese adults with T2D, results of the OUTSTAND-2 phase III trial have shown. Treatment differences are also in favour of HRS-7535, with superiority at the 90-mg dose.

16 Oct 2026